Stifel Nicolaus reiterated their buy rating on shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) in a report issued on Wednesday morning. The firm currently has a $13.00 target price on the biopharmaceutical company’s stock.
Several other equities research analysts have also issued reports on the stock. Chardan Capital dropped their target price on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a neutral rating for the company in a research report on Monday, August 15th. Leerink Swann restated a buy rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. Cowen and Company restated a buy rating on shares of Dicerna Pharmaceuticals in a report on Friday, August 5th. Finally, Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, August 25th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $11.85.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up 9.49% during trading on Wednesday, reaching $5.19. 560,779 shares of the company’s stock traded hands. The company’s 50-day moving average is $3.53 and its 200 day moving average is $3.89. Dicerna Pharmaceuticals has a 52-week low of $2.69 and a 52-week high of $15.93. The company’s market cap is $107.71 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.09. Equities analysts forecast that Dicerna Pharmaceuticals will post ($3.17) EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its position in shares of Dicerna Pharmaceuticals by 44.9% in the second quarter. Dimensional Fund Advisors LP now owns 34,273 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 10,616 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at approximately $160,000. A.R.T. Advisors LLC purchased a new position in shares of Dicerna Pharmaceuticals during the second quarter valued at approximately $170,000. Paloma Partners Management Co purchased a new position in shares of Dicerna Pharmaceuticals during the second quarter valued at approximately $183,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at approximately $343,000. 62.38% of the stock is currently owned by institutional investors.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.